Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation  by Gut, J. et al.
Volume 173, number 2 FEBS 1680 August 1984 
~~briso~uin~-type polymorphism of drug oxidation: purification 
from human liver of a c~ochrom~ P450 isozym~ with high 
activity for bufuralol hydroxylation 
J. Gut, R. Gasser, P. Dayer, T. Kronbach, T. Catin and U.A. Meyer* 
department of Pharmacology, &center of ihe University, 4056 Base& Switzerland 
Received 7 June 1984 
Indirect evidence suggests hat the genetically defective metabolism of drugs such as debrisoquine and 
bufuralol observed in up to 10% of the population (poor metabolizers) is caused by the absence or 
functional deficiency of a cytochrome P450 isozyme. Using bufur~oi-I ‘-hydroxy~ation to carbinol to 
optimize the procedure, 3 cytochrome P450 isozymes (P45OA, P450buf, P45OC) were purified to apparent 
electrophoretic homogeneity from human liver microsomes. P450buf had a specific activity of 20.3 nmol 
carbinol. nmol P450-‘. 15 min-’ as compared to microsomes (10.0 nmol carbinol snmol 
P450-’ * 15 min-‘) when (+)-bufuralol was used as substrate. The stereoselective metabolism of (-)- and 
(+)-bufuraIo1 to carbinol by purified P450buf [( -)/( +) ratio: 0.131 was strikingly different from that in 
the microsomes of either an extensive [( - )/( +) ratio: 0.41 or poor metabolizer [( - )/( + ) ratio: 0.831 of 
bufuralol. We propose that this isozyme is the major bufuralol and debrisoquine hydroxylating species and 
is the target of the genetic deficiency. 
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1. INTRODUCTION 
Drug biotransformation by hepatic polysub- 
strate monooxygenases (trivial name: cytochrome 
P450) is a major determinant of the therapeutic 
and toxic responses to a broad variety of clinically 
important drugs. Recent indirect evidence from 
this and other laboratories suggest hat a common 
genetic polymorphism causing impaired biotrans- 
formation of debrisoquine, sparteine, bufur~ol 
and a number of other drugs [l-7] is caused by the 
absence or functional deficiency of a cytochrome 
P450 isozyme [S-lo]. This polymorphism occurs 
with a frequency of up to 1OYo in European popu- 
lations and separates individuals into ‘extensive 
(EM’ and ‘poor (PM)’ metabolizer phenotypes for 
the metabolism of these drugs. The defect is in- 
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herited as an autosomal-recessive trait [ 1 l]. Its 
clinical relevance has been demonstrate [4,5,12]. 
To elucidate the molecular basis of this genetic 
defect, the cytochrome P450 isozyme(s) responsi- 
ble for this monooxygenase activity has (have) to 
be isolated from human tissue and characterized. 
2. EXPERIMENTAL 
Mi~rosomes from 300 g (wet wt) liver of kidney 
transplant donors (KDL) were prepared as in [8]. 
The purification of a cytochrome P450 with high 
bufuralol hydroxylation activity (P45Obuf) was 
achieved by following the reconstituted specific ac- 
tivity of bufuralol-1 ’ -hydroxylation to carbinol of 
the individual fractions. Briefly, after cholate 
soiubilization a microsomal supernatant contain- 
ing approx, 1000 nmol P450 was applied to an w- 
aminooctyl Sepharose-4B column (3.6 x 30 cm, 
pH 7.25 [13]). P450-containing fractions were 
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eluted with buffer containing 0.06 and 0.5% (w/v) 
Emulgen 913, respectively [13,141. The latter frac- 
tion was then applied to a hydroxyapatite column 
(2.6 x 8 cm, pH 7.25) and P450 fractions were 
eluted stepwise with 40, 90, 180 and 300 mM po- 
tassium phosphate 1141. After dialysis the fraction 
obtained at 90 mM phosphate was loaded onto a 
DE-Sepharose CL-6B-column (1.6 x 10 cm, pH 
7.8) and a linear gradient of O-250 mM NaCl led 
to the elution of P4SObuf at -40 mM NaCl. Cyto- 
chrome P450buf showed a single homogeneous 
band on SDS-PAGE when 5 pg protein were ap- 
plied to a I mm gel. Furthermore, two other elec- 
trophoretically homogeneous cytochromes, P450A 
and P45OC, were purified from one liver. They 
were obtained by chromatography on DE-Sepha- 
rose CL-6B of the fractions eluting at 90 and 180 
mM phosphate from the hydroxyapatite column 
NADPH cytochrome P4.50 reductase (P450 
reductase) was purified from rat or human liver 
microsomes as in 1151. The preparations had 
specific activities of 40 units/mg (nmol cyto- 
chrome c reduced -min- r, RT) and 10 units/mg, 
respectively. They could be used interchangeably 
in reconstitution experiments. 
Detergents were removed from the purified pro- 
tein fractions with Bio-Beads SM-2 1161. For 
reconstitution of monooxygenase activity lo-20 
pmol P450,0.3 units P450 reductase, 20 #g/ml of 
dilauroyl-Lo-phosphatidylcholine, 5 mM MgC12, 
5 mM isocitrate, 1 unit isocitrate dehydrogenase, 
1 mM NADPH and the indicated substrate con- 
centration were incubated in a final volume of 
250 ~1 of 0.1 M potassium phosphate (pH 7.41, 
20% (v/v) glycerol. The system was preincubated 
at 4°C for 30 min prior to addition of the 
NADPH-regenerating system and at 37°C for 5 
min before addition of the substrate. After I5 min 
of incubation at 37°C with gentle shaking, a 100 ~1 
aliquot was mixed with 10 ,ul of 12% (w/v) HCl04, 
proteins were sedimented and the supernatant 
stored at - 80°C until analysis. The carbinol meta- 
bolite was determined by reversed phase HPLC on 
a Spherisorb ODS (5 Frn) column with fluor- 
escence detection at the excitation/emission wave- 
length pair of 252/303 nm. The rate of bufur- 
alol-1 ‘-hydroxylation was linear with time up to 
20 min and with P450buf up to 25 pmol/250& 
The reaction was dependent on NADPH and in- 
hibited by CO. NADH did not support the reac- 
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tion. When the bufuralol-1 ‘-hydroxylation assay 
was carried out in microsomes, 200 gg microsomal 
protein in 1 ml of 0.1 M sodium phosphate (pH 
7.4) was incubated. 
For screening activities in individual fractions at 
early stages of the purification (table 1) the assay 
was not optimized for linearity with time and pro- 
tein concentration. This explains the different ac- 
tivities for carbinol production by P45Obuf in table 
1 vs table 2. 
Ethoxycoumarin-O-deethylase activity was 
measured as in [17] with the reconstituted system 
containing 50 pmol P450 isozymes and P450 
reductase (0.8 units) in 1 ml final volume. 
Benzphetamine-N-demethylation was determined 
using 150 pmol P450 and 0.4 units P450 reductase 
in 300 /cl final volume [18]. Both activities were 
linear with time and protein content. P450 concen- 
tration was determined by CO-binding spectra 
(191. Protein was determined according to [ZO]. 
Racemic, (i-j-, (-)-, and 1 ‘-OH-bufuralol car- 
binol were kindly provided by Hoffmann-La 
Roche, Basel, Switzerland, and Welwyn Garden 
City, England (Dr R. Francis). 
3. RESULTS AND DISCUSSION 
By monitoring the activity of bufuralol-1 ‘- 
hydroxylation in the individual column eluates we 
have developed a procedure which results in the 
reproducible purification from different human 
livers of a P450 isozyme (P45Obuf) with a high 
turnover number for this reaction. P450buf was 
homogeneous on SDS-PAGE but apparently had 
lost some prosthetic heme resnhing in a decreased 
heme-CO binding complex in relation to the pro- 
tein content (table 1). Two additional isozymes 
with low turnover numbers for bufuralol-l’- 
hydroxylation and variant activities towards benz- 
phetamine and ethoxycoumarin also were purified 
from one liver (table 2). 
Many monooxygenase reactions are character- 
ized by stereospecific recognition of substrates 
with as~metric carbon centers. When the pure 
enantiomers of bufuralol were used as substrates, 
the reconstituted P450buf showed strikingly in- 
creased selectivity for the (+ ) enantiomer with a 
3-4-fold lower ( - )/( + ) ratio than the microsomes 
from the same extensive metabolizer liver (table 3). 
Volume 173, number 2 FEBS LETTERS August 1984 
Table 1 
Purification of cytochrome P450buf from human liver 
Protein 
(ms) 
P450 
(nmol) 
Specific 
content 
(nmol P450/ 
mg protein) 
Yield nmol carbinol . 
(‘J7o P450) nmol-’ P450.h-’ 
Microsomes 
w-Aminooctyl Sepharose-4B 
(eluate at 0.5% Emulgen) 
Hydroxyapatite 
(eluate at 90 mM phosphate) 
DE-Sepharose CL-6B 
(eluate at 40 mM NaCl) 
1025 947 0.92 100 6.0 
89 163 1.83 17.2 1.4 
15.5 20.2 1.3 2.1 5.1 
8.4 9.6 1.13 1.0 16.8 
Bufuralol-1 ‘-hydroxylation was carried out in a system containing 150 pmol P450,0.8 units NADPH cytochrome P450 
reductase and 1 mM racemic bufuralol as substrate. Incubation was for 1 h. The other assay conditions were as 
described in the text 
Thus, in P450buf a highly stereoselective compo- 
nent of the reaction was isolated. By contrast, 
microsomes of a poor metabolizer demonstrated 
minimal stereoselectivity consistent with the ab- 
sence or functional deficiency of this stereoselec- 
tive component. 
Moreover, whereas the rate of formation of car- 
binol from the (-)-bufuralol was similar for 
P450buf, for extensive metabolizer and poor 
metabolizer microsomes the carbinol production 
rate from (+)-bufuralol showed marked dif- 
ferences (table 3). 
These findings suggest a functional deficiency or 
a lack of P450buf specific for (+)- 
bufuralol-1 ’ -hydroxylation in poor metabolizer 
livers as the cause of the debrisoquine-type 
polymorphism. The purified isozyme will now 
serve to develop immunological and gene probes to 
investigate the molecular basis of this common 
defect of drug metabolism. 
Table 2 
Molecular mass, specific content and enzymatic activities of 3 purified cytochrome P450 isozymes 
Molecular 
mass 
(kDa) 
(SDS- 
PAGE) 
Specific 
content 
(nmol P450 - 
mg-’ protein) 
P45Obufb 50 1.13 8.7 4.1 n.d. 
P450Ac 55 4.6 n.d. 7.2 41.0 
P45OC 55 2.25 0.49 5.1 n.d. 
Substrates 
Bufuralol’ 
(nmol carbinol . 
nmol- ’ P450. 
15 min-‘) 
dBenzphetamine 7-Ethoxycoumarin 
(nmol HCHO - (pmol 7-OH-coumarin . 
nmol-’ P450*min-‘) nmol-’ P450*min-r) 
a Racemic mixture of bufuralol 
b P450buf was purified from kidney donor livers 6 and 8 
’ P45OA and P45OC were purified from kidney donor liver 6 
d n.d., not detectable 
289 
Volume 173, number 2 FEBS LETTERS August 1984 
Table 3 
St~r~osele~t~ve metabolism of (+)- and (-)-bufuralol by extensive (EM)-, poor (PM)-metaboIi~er microsomes and 
reconstituted ~4S~buf 
( - )-3ufuralol ( + )-Bufuralol 
(640 trM) (640 FM) 
(nmot carbinaf * (nmol carbinoi s ( - $4 + ) ratio 
nmol-” P450~ 15 min-‘f urnal-’ F450.15 min-‘) 
~e~oast~tut~d P4~~buf 2.65 20.3 0.13 
(2.5 -2.8 )” (16.1-24.5)’ (cl.ll-0.15) 
E~~~mierosomes 3.75 IO.0 0.405 
(4.04-3.46fa ( 7.2-12.9)a (0.5 -0.31) 
PM-mi~rosomes 2.@ 2.4 0.83 
a Values in parentheses denote the range of Y max derived from two experiments in which the concentratiou f substrate 
was varied from I to 640,&l 
b Only a single ~~erim~at was done because of a limited doubt of tissue 
Assay conditions are as described except hat the incubation time for microsomes was 40 min. 
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